Given that immune cells share many metabolic ways that are critical for tumor cells survival, the therapeutic window of metabolic drugs is usually narrow, which may lead to severe toxicity.43 Metabolic plasticity remains a challenge when targeting tumor-specific metabolism.44 Due to the lack of inhibitors targeting metabolite G3P as well as metabolic enzyme GPD1L, we targeted upstream VCP as a therapeutic target. Here, GPD1L is linked to neoplasm.